Clinical trial
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study to Evaluate the Safety, and Efficacy of AD17002 (LTh[αK]) Intranasal Spray in Male and Female Participants Aged 18 to 65 Years With Mild to Moderate COVID 19
NCT05541510 is registered in ClinicalTrials.gov with Advagene Biopharma Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study to Evaluate the Safety, and Efficacy of AD17002 (LTh[αK]) Intranasal Spray in Male and Female Participants Aged 18 to 65 Years With Mild to Moderate COVID 19
- Lead sponsor
- Advagene Biopharma Co. Ltd.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- December 1, 2022
- Completion date
- August 25, 2024
- Enrollment
- 180 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.